Načítá se...

Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions

OBJECTIVE: To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) in patients with prior taxane HSR. METHODS: From 2005 to 2015, all patients who received nab-paclitaxel for a gynecologic malignancy were identified. Chart abstraction included pathology, prior therapy, indicat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Gynecol Oncol
Hlavní autoři: Maurer, Kathryn, Michener, Chad, Mahdi, Haider, Rose, Peter G.
Médium: Artigo
Jazyk:Inglês
Vydáno: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2017
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5447141/
https://ncbi.nlm.nih.gov/pubmed/28541630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3802/jgo.2017.28.e38
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!